The long term effectiveness of choiinesterase inhibitors in Alzheimer's disease (AD) is a matter of controversy To evaluate the potential long-term effects of eptastigmme, a new choiinesterase inhibitor, we evaluated data obtained from the open label extension phase of a 25-week, double-blind, placebo-controlled multicenter study in 320 patients with probable AD. In the double-blind phase of the study, patients received placebo t.i.d. (n=106) or eptastigmine 10 mg t.i.d. (n=105) or eptastigmine 15 mg t i.d. (n=109). At the end of the double-blind phase, patients receiving 15 mg t.i.d. performed significantly better than placebo-treated patients on the ADAS-Cog scale In the open label extension phase, patients received eptastigmine 10 mg t.i.d. Twenty-six patients (lOmales and 16 females) with a mean MMSE score of 20 9 and a mean age of 68 years at baseline, completed two years of treatment. The drug was well tolerated At the end of the two year-treatment they showed a worsening of 76 points on ADAS-Cog, 37 points on MMSE and 2.2 points on Instrumental Activities of Daily Living scale Patients with mild to moderate AD treated with placebo are expected to have a worsening of approximately 7.0 points per year on ADAS-Cog, 3.8 points on MMSE and 3.5 points on IADL Compared to published deterioration rates, patients treated with eptastigmine for two years had a benefit of 6.4 points on ADAS-Cog, 39 points on MMSE and 4.8 points on IADL These benefits translate to about one year difference between eptastigmme-treated patients and placebo-treated patients Our data support the view that AD patients derive long-term benefit from eptastigmine.
|Number of pages||1|
|Journal||Italian Journal of Neurological Sciences|
|Publication status||Published - 1997|
ASJC Scopus subject areas
- Clinical Neurology